Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 20

1.

Ligands for mapping alphavbeta3-integrin expression in vivo.

Schottelius M, Laufer B, Kessler H, Wester HJ.

Acc Chem Res. 2009 Jul 21;42(7):969-80. doi: 10.1021/ar800243b.

PMID:
19489579
[PubMed - indexed for MEDLINE]
2.

Radiolabelled RGD peptides and peptidomimetics for tumour targeting.

Haubner R, Decristoforo C.

Front Biosci (Landmark Ed). 2009 Jan 1;14:872-86. Review.

PMID:
19273105
[PubMed - indexed for MEDLINE]
3.

(68)Ga-labeled cyclic RGD dimers with Gly3 and PEG4 linkers: promising agents for tumor integrin alphavbeta3 PET imaging.

Liu Z, Niu G, Shi J, Liu S, Wang F, Liu S, Chen X.

Eur J Nucl Med Mol Imaging. 2009 Jun;36(6):947-57. doi: 10.1007/s00259-008-1045-1. Epub 2009 Jan 22.

PMID:
19159928
[PubMed - indexed for MEDLINE]
4.

Patterns of alphavbeta3 expression in primary and metastatic human breast cancer as shown by 18F-Galacto-RGD PET.

Beer AJ, Niemeyer M, Carlsen J, Sarbia M, Nährig J, Watzlowik P, Wester HJ, Harbeck N, Schwaiger M.

J Nucl Med. 2008 Feb;49(2):255-9. doi: 10.2967/jnumed.107.045526. Epub 2008 Jan 16.

PMID:
18199623
[PubMed - indexed for MEDLINE]
Free Article
5.

Comparison of integrin alphaVbeta3 expression and glucose metabolism in primary and metastatic lesions in cancer patients: a PET study using 18F-galacto-RGD and 18F-FDG.

Beer AJ, Lorenzen S, Metz S, Herrmann K, Watzlowik P, Wester HJ, Peschel C, Lordick F, Schwaiger M.

J Nucl Med. 2008 Jan;49(1):22-9. Epub 2007 Dec 12.

PMID:
18077538
[PubMed - indexed for MEDLINE]
Free Article
6.

[18F]galacto-RGD positron emission tomography for imaging of alphavbeta3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck.

Beer AJ, Grosu AL, Carlsen J, Kolk A, Sarbia M, Stangier I, Watzlowik P, Wester HJ, Haubner R, Schwaiger M.

Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6610-6.

PMID:
18006761
[PubMed - indexed for MEDLINE]
Free Article
7.

Positron emission tomography using [18F]Galacto-RGD identifies the level of integrin alpha(v)beta3 expression in man.

Beer AJ, Haubner R, Sarbia M, Goebel M, Luderschmidt S, Grosu AL, Schnell O, Niemeyer M, Kessler H, Wester HJ, Weber WA, Schwaiger M.

Clin Cancer Res. 2006 Jul 1;12(13):3942-9.

PMID:
16818691
[PubMed - indexed for MEDLINE]
Free Article
8.

Biodistribution and pharmacokinetics of the alphavbeta3-selective tracer 18F-galacto-RGD in cancer patients.

Beer AJ, Haubner R, Goebel M, Luderschmidt S, Spilker ME, Wester HJ, Weber WA, Schwaiger M.

J Nucl Med. 2005 Aug;46(8):1333-41.

PMID:
16085591
[PubMed - indexed for MEDLINE]
Free Article
9.

Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD.

Haubner R, Weber WA, Beer AJ, Vabuliene E, Reim D, Sarbia M, Becker KF, Goebel M, Hein R, Wester HJ, Kessler H, Schwaiger M.

PLoS Med. 2005 Mar;2(3):e70. Epub 2005 Mar 29.

PMID:
15783258
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Radiolabeled tracers for imaging of tumor angiogenesis and evaluation of anti-angiogenic therapies.

Haubner R, Wester HJ.

Curr Pharm Des. 2004;10(13):1439-55. Review.

PMID:
15134568
[PubMed - indexed for MEDLINE]
11.

Integrins: roles in cancer development and as treatment targets.

Jin H, Varner J.

Br J Cancer. 2004 Feb 9;90(3):561-5. Review.

PMID:
14760364
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Alpha(v)beta(3) integrin in angiogenesis and restenosis.

Kerr JS, Mousa SA, Slee AM.

Drug News Perspect. 2001 Apr;14(3):143-50.

PMID:
12819820
[PubMed]
13.

Integrin alpha v beta 3 as a therapeutic target for blocking tumor-induced angiogenesis.

Kumar CC.

Curr Drug Targets. 2003 Feb;4(2):123-31. Review.

PMID:
12558065
[PubMed - indexed for MEDLINE]
14.

alphav Vitronectin receptors in vascular-mediated disorders.

Mousa SA.

Med Res Rev. 2003 Mar;23(2):190-9. Review.

PMID:
12500288
[PubMed - indexed for MEDLINE]
15.

Suppression of tumor angiogenesis through the inhibition of integrin function and signaling in endothelial cells: which side to target?

Rüegg C, Dormond O, Foletti A.

Endothelium. 2002;9(3):151-60. Review.

PMID:
12380640
[PubMed - indexed for MEDLINE]
16.

Integrin alpha V beta 3 as a target for treatment of rheumatoid arthritis and related rheumatic diseases.

Wilder RL.

Ann Rheum Dis. 2002 Nov;61 Suppl 2:ii96-9. Review.

PMID:
12379637
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics.

Haubner R, Wester HJ, Burkhart F, Senekowitsch-Schmidtke R, Weber W, Goodman SL, Kessler H, Schwaiger M.

J Nucl Med. 2001 Feb;42(2):326-36.

PMID:
11216533
[PubMed - indexed for MEDLINE]
Free Article
18.

Integrins and bone--cell adhesion and beyond.

Grzesik WJ.

Arch Immunol Ther Exp (Warsz). 1997;45(4):271-5. Review.

PMID:
9523000
[PubMed - indexed for MEDLINE]
19.

Tumor angiogenesis and the role of vascular cell integrin alphavbeta3.

Varner JA, Cheresh DA.

Important Adv Oncol. 1996:69-87. Review.

PMID:
8791129
[PubMed - indexed for MEDLINE]
20.

Integrins: versatility, modulation, and signaling in cell adhesion.

Hynes RO.

Cell. 1992 Apr 3;69(1):11-25. Review. No abstract available.

PMID:
1555235
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk